Concomitant medical treatment was in accordance with the 2016 ESC Guidelines for the management and treatment of atrial fibrillation [15]; 72% of the patients were taking a betablocker, 54% an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and 19% a calcium channel blocker. Here, ACE is linked to atrial fibrillation.